More Articles

4SC and PACT complete virtual HTP drug screening pilot

Editor, (May 17, 2001)

Through a combination of 4SC's proprietary virtual-high-throughput technology and PACT's XPU microprocessor technology, the alliance contends it has been able to increase the speed of computer

Agilent and Merck to continue gene expression analysis solutions alliance

Editor, (May 17, 2001)

On May 11, Merck and Rosetta announced an agreement under which Merck will acquire Rosetta.

Schering-Plough extends deal with FreeMarkets

Editor, (May 15, 2001)

Commercial

Wyeth Lederle signs Adera to develop Internet and IT initiatives

Editor, (May 15, 2001)

Adera will be responsible for the management and quality control of Wyeth Lederle's Web site and will also be involved in the strategic work to develop Wyeth Lederle's future Internet and IT i
Commercial

Aventis pilots new initiative for physician interaction

Editor, (May 15, 2001)

Using a PC and browser, physicians go to a secure Web site, log-on, and connect with a medical information specialist. Once connected, the

MGI PHARMA chooses EventNet for adverse events reporting

Editor, (May 15, 2001)

EventNet is used to actively manage, analyze and report adverse events, product complaints and medical communication requests.

Cellular Genomics announces agreement with InforMax

Editor, (May 15, 2001)

GenoMax is a modular family of tools, each designed to work with one or more types of genomic and proteomic data, including sequence information, gene expression data, and protein structure.
Commercial

IBM forms collaboration with PatientKeeper for mobile healthcare platform

Editor, (May 15, 2001)

With personal digital assistants and enterprise software for PatientKeeper, clinicians can access a range of patient care and administrative functions, including ordering and reviewing lab tests, pres

BioWisdom forms partnership with Abcam

Editor, (May 14, 2001)

This partnership will enable users of BioWisdom's Discovery Portfolio to identify and purchase Abcam's antibody reagents.

Merck acquires Rosetta Inpharmatics

Editor, (May 13, 2001)

Each share of Rosetta stock will be converted into 0.2352 shares of Merck stock, which represents a value of $18 per share based on Merck's May 10, 2001 closing price.

Pages